Adenoid cystic carcinomas constitute a genomically distinct subgroup of triple-negative and basal-like breast cancers

Journal of Pathology

Volumn 226, Issue 1, 2012, Pages 84-96

  Wetterskog, Daniel ^a   Lopez Garcia, Maria Angeles ^a,b   Lambros, Maryou B ^a   A'Hern, Roger ^a   Geyer, Felipe C ^a   Milanezi, Fernanda ^a   Cabral, Maria C ^a   Natrajan, Rachael ^a   Gauthier, Arnaud ^a   Shiu, Kai Keen ^a   Orr, Nicholas ^a   Shousha, Sami ^c   Gatalica, Zoran ^d   MacKay, Alan ^a   Palacios, Jose ^b   Reis Filho, Jorge S ^a   Weigelt, Britta ^e  

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^b HOSPITAL UNIVERSITARIO VIRGEN DEL ROCÍO   (Spain)

^c IMPERIAL COLLEGE HEALTHCARE NHS TRUST   (United Kingdom)

^d CREIGHTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e IMPERIAL CANCER RESEARCH FUND   (United Kingdom)

Author keywords

adenoid cystic carcinoma; breast cancer; comparative genomic hybridization; fusion genes; genetics; microarrays; MYB NFIB

Indexed keywords

BRCA1 PROTEIN; CYTOKERATIN 14; CYTOKERATIN 17; CYTOKERATIN 18; CYTOKERATIN 5; CYTOKERATIN 6; CYTOKERATIN 7; CYTOKERATIN 8; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; FIBROBLAST GROWTH FACTOR RECEPTOR 1; KI 67 ANTIGEN; PROGESTERONE RECEPTOR; PROTEIN MYB; PROTEIN P53; PROTEIN P63; RNA; VASCULOTROPIN RECEPTOR;

ADENOID CYSTIC CARCINOMA; ARTICLE; BASAL LIKE BREAST CANCER; BREAST CANCER; CANCER GRADING; COMPARATIVE GENOMIC HYBRIDIZATION; CONTROLLED STUDY; FLUORESCENCE IN SITU HYBRIDIZATION; FUSION GENE; GENE DOSAGE; GENE EXPRESSION; GENE TRANSLOCATION; GENOMICS; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; INTRADUCTAL CARCINOMA; INVASIVE CARCINOMA; MICRODISSECTION; MYB NFIB FUSION GENE; ONCOGENE C KIT; PHENOTYPE; PREVALENCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TISSUE MICROARRAY; TRIPLE NEGATIVE BREAST CANCER;

BREAST NEOPLASMS; CARCINOMA, ADENOID CYSTIC; CARCINOMA, DUCTAL, BREAST; FEMALE; GENE DOSAGE; GENE EXPRESSION PROFILING; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION, FLUORESCENCE; MICRODISSECTION; ONCOGENE PROTEINS, FUSION; RECEPTOR, ERBB-3; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TISSUE ARRAY ANALYSIS;

EID: 82755177882     PISSN: 00223417     EISSN: 10969896     Source Type: Journal    
DOI: 10.1002/path.2974     Document Type: Article

References (47)

1. Marchio C, Weigelt B, Reis-Filho JS,. Adenoid cystic carcinomas of the breast and salivary glands (or 'The strange case of Dr Jekyll and Mr Hyde' of exocrine gland carcinomas). J Clin Pathol 2010; 63: 220-228.
2. Arpino G, Clark GM, Mohsin S, et al., Adenoid cystic carcinoma of the breast: molecular markers, treatment, and clinical outcome. Cancer 2002; 94: 2119-2127. (Pubitemid 34411967)
3. Bennett AK, Mills SE, Wick MR,. Salivary-type neoplasms of the breast and lung. Semin Diagn Pathol 2003; 20: 279-304. (Pubitemid 37523515)
4. Azoulay S, Lae M, Freneaux P, et al., KIT is highly expressed in adenoid cystic carcinoma of the breast, a basal-like carcinoma associated with a favorable outcome. Mod Pathol 2005; 18: 1623-1631. (Pubitemid 41670663)
5. Crisi GM, Marconi SA, Makari-Judson G, et al., Expression of c-kit in adenoid cystic carcinoma of the breast. Am J Clin Pathol 2005; 124: 733-739. (Pubitemid 41532508)
6. Mastropasqua MG, Maiorano E, Pruneri G, et al., Immunoreactivity for c-kit and p63 as an adjunct in the diagnosis of adenoid cystic carcinoma of the breast. Mod Pathol 2005; 18: 1277-1282. (Pubitemid 41348645)
7. Weigelt B, Horlings HM, Kreike B, et al., Refinement of breast cancer classification by molecular characterization of histological special types. J Pathol 2008; 216: 141-150.
8. Foulkes WD, Smith IE, Reis-Filho JS,. Triple-negative breast cancer. N Engl J Med 2010; 363: 1938-1948.
9. Weigelt B, Geyer FC, Reis-Filho JS,. Histological types of breast cancer: how special are they? Mol Oncol 2010; 4: 192-208.
10. Weigelt B, Reis-Filho JS,. Histological and molecular types of breast cancer: is there a unifying taxonomy? Nature Rev Clin Oncol 2009; 6: 718-730.
11. Persson M, Andren Y, Mark J, et al., Recurrent fusion of MYB and NFIB transcription factor genes in carcinomas of the breast and head and neck. Proc Natl Acad Sci U S A 2009; 106: 18740-18744.
12. Mitani Y, Li J, Rao PH, et al., Comprehensive analysis of the MYB-NFIB gene fusion in salivary adenoid cystic carcinoma: incidence, variability, and clinicopathologic significance. Clin Cancer Res 2010; 16: 4722-4731.
13. West RB, Kong C, Clarke N, et al., MYB expression and translocation in adenoid cystic carcinomas and other salivary gland tumors with clinicopathologic correlation. Am J Surg Pathol 2011; 35: 92-99.
14. Bernheim A, Toujani S, Saulnier P, et al., High-resolution array comparative genomic hybridization analysis of human bronchial and salivary adenoid cystic carcinoma. Lab Invest 2008; 88: 464-473. (Pubitemid 351581453)
15. Mark HF, Hanna I, Gnepp DR,. Cytogenetic analysis of salivary gland type tumors. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 1996; 82: 187-192. (Pubitemid 126808154)
16. Turner NC, Reis-Filho JS, Russell AM, et al., BRCA1 dysfunction in sporadic basal-like breast cancer. Oncogene 2007; 26: 2126-2132. (Pubitemid 46514749)
17. Natrajan R, Lambros MB, Geyer FC, et al., Loss of 16q in high grade breast cancer is associated with estrogen receptor status: evidence for progression in tumors with a luminal phenotype? Genes Chromosomes Cancer 2009; 48: 351-365.
18. Natrajan R, Lambros MB, Rodriguez-Pinilla SM, et al., Tiling path genomic profiling of grade 3 invasive ductal breast cancers. Clin Cancer Res 2009; 15: 2711-2722.
19. Andre F, Job B, Dessen P, et al., Molecular characterization of breast cancer with high-resolution oligonucleotide comparative genomic hybridization array. Clin Cancer Res 2009; 15: 441-451.
20. Lopez-Garcia MA, Geyer FC, Lacroix-Triki M, et al., Breast cancer precursors revisited: molecular features and progression pathways. Histopathology 2010; 57: 171-192.
21. Chin K, DeVries S, Fridlyand J, et al., Genomic and transcriptional aberrations linked to breast cancer pathophysiologies. Cancer Cell 2006; 10: 529-541. (Pubitemid 44854748)
22. Elston CW, Ellis IO,. Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology 1991; 19: 403-410.
23. Ro JY, Silva EG, Gallager HS,. Adenoid cystic carcinoma of the breast. Hum Pathol 1987; 18: 1276-1281. (Pubitemid 18018959)
24. Nielsen TO, Hsu FD, Jensen K, et al., Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma. Clin Cancer Res 2004; 10: 5367-5374. (Pubitemid 39100473)
25. Lacroix-Triki M, Suarez PH, MacKay A, et al., Mucinous carcinoma of the breast is genomically distinct from invasive ductal carcinomas of no special type. J Pathol 2010; 222: 282-298.
26. Hammond ME, Hayes DF, Dowsett M, et al., American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. J Clin Oncol 2010; 28: 2784-2795.
27. Wolff AC, Hammond ME, Schwartz JN, et al., American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol 2007; 25: 118-145. (Pubitemid 350003059)
28. Reis-Filho JS, Pinheiro C, Lambros MB, et al., EGFR amplification and lack of activating mutations in metaplastic breast carcinomas. J Pathol 2006; 209: 445-453. (Pubitemid 44194559)
29. Geyer FC, Weigelt B, Natrajan R, et al., Molecular analysis reveals a genetic basis for the phenotypic diversity of metaplastic breast carcinomas. J Pathol 2010; 220: 562-573.
30. Marchio C, Iravani M, Natrajan R, et al., Mixed micropapillary-ductal carcinomas of the breast: a genomic and immunohistochemical analysis of morphologically distinct components. J Pathol 2009; 218: 301-315.
31. Arriola E, Marchio C, Tan DS, et al., Genomic analysis of the HER2/TOP2A amplicon in breast cancer and breast cancer cell lines. Lab Invest 2008; 88: 491-503. (Pubitemid 351581454)
32. Weigelt B, Geyer FC, Natrajan R, et al., The molecular underpinning of lobular histological growth pattern: a genome-wide transcriptomic analysis of invasive lobular carcinomas and grade- and molecular subtype-matched invasive ductal carcinomas of no special type. J Pathol 2010; 220: 45-57.
33. Lambros MB, Simpson PT, Jones C, et al., Unlocking pathology archives for molecular genetic studies: a reliable method to generate probes for chromogenic and fluorescent in situ hybridization. Lab Invest 2006; 86: 398-408.
34. Lambros MB, Natrajan R, Geyer FC, et al., PPM1D gene amplification and overexpression in breast cancer: a qRT-PCR and chromogenic in situ hybridization study. Mod Pathol 2010; 23: 1334-1345.
35. Coe BP, Ylstra B, Carvalho B, et al., Resolving the resolution of array CGH. Genomics 2007; 89: 647-653. (Pubitemid 46589944)
36. Gunnarsson R, Staaf J, Jansson M, et al., Screening for copy-number alterations and loss of heterozygosity in chronic lymphocytic leukemia-a comparative study of four differently designed, high resolution microarray platforms. Genes Chromosomes Cancer 2008; 47: 697-711. (Pubitemid 351847582)
37. Tan DS, Lambros MB, Natrajan R, et al., Getting it right: designing microarray (and not 'microawry') comparative genomic hybridization studies for cancer research. Lab Invest 2007; 87: 737-754. (Pubitemid 47077258)
38. Courjal F, Cuny M, Simony-Lafontaine J, et al., Mapping of DNA amplifications at 15 chromosomal localizations in 1875 breast tumors: definition of phenotypic groups. Cancer Res 1997; 57: 4360-4367. (Pubitemid 27413447)
39. Silver DP, Richardson AL, Eklund AC, et al., Efficacy of neoadjuvant cisplatin in triple-negative breast cancer. J Clin Oncol 2010; 28: 1145-1153.
40. Rakha EA, El-Sheikh SE, Kandil MA, et al., Expression of BRCA1 protein in breast cancer and its prognostic significance. Hum Pathol 2008; 39: 857-865.
41. Rakha EA, Reis-Filho JS, Ellis IO,. Basal-like breast cancer: a critical review. J Clin Oncol 2008; 26: 2568-2581.
42. Stephens PJ, McBride DJ, Lin ML, et al., Complex landscapes of somatic rearrangement in human breast cancer genomes. Nature 2009; 462: 1005-1010.
43. Tognon C, Knezevich SR, Huntsman D, et al., Expression of the ETV6-NTRK3 gene fusion as a primary event in human secretory breast carcinoma. Cancer Cell 2002; 2: 367-376. (Pubitemid 41039103)
44. Lae M, Freneaux P, Sastre-Garau X, et al., Secretory breast carcinomas with ETV6-NTRK3 fusion gene belong to the basal-like carcinoma spectrum. Mod Pathol 2009; 22: 291-298.
45. Makretsov N, He M, Hayes M, et al., A fluorescence in situ hybridization study of ETV6-NTRK3 fusion gene in secretory breast carcinoma. Genes Chromosomes Cancer 2004; 40: 152-157. (Pubitemid 38579884)
46. Letessier A, Ginestier C, Charafe-Jauffret E, et al., ETV6 gene rearrangements in invasive breast carcinoma. Genes Chromosomes Cancer 2005; 44: 103-108. (Pubitemid 41060201)
47. Ashworth A, Lord CJ, Reis-Filho JS,. Genetic interactions in cancer progression and treatment. Cell 2011; 145: 30-38.